Study authors assessed the long-term effectiveness and safety of GH in real-life clinical practice and whether age mattered at the time of treatment initiation.
There has been a significant surge in the use of growth hormone to improve athletic ability and combat aging despite no clear supporting evidence.
Patient evaluation, follow-up testing, and treatment differ based on lesion size and presence of hormone abnormalities with pituitary incidentalomas.
Switching from daily human growth hormone to once-weekly TransCon growth hormone treatment resulted in similar safety and efficacy outcomes in pediatric patients.
The FDA has granted Orphan Drug designation to TransCon hGH (lonapegsomatropin; Ascendis Pharma), a long-acting prodrug of somatropin, for the treatment for growth hormone deficiency.
A once-weekly growth hormone replacement therapy demonstrated superiority over placebo for patients with adult growth hormone deficiency.
Growth hormone replacement can raise irisin levels in children with growth hormone deficiency.
Normal height velocity can be maintained in prepubertal children during the catch-up growth period by reducing growth hormone dosage by 50%.
Primary cancer rates and mortality risk were no higher for pediatric patients treated with growth hormone therapy.
Investigators examined the reliability of the clonidine test in children with short stature who had been evaluated for suspected growth hormone deficiency.
